## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of April 2016

Commission File Number 001-16174

# TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Translation of registrant's name into English)

5 Basel Street, P.O. Box 3190 Petach Tikva 4951033 Israel (Address of principal executive offices)

#### **CONTENTS**

At the 2016 Annual Meeting of Shareholders of Teva Pharmaceutical Industries Limited, which was held on April 18, 2016, all proposals were approved by the required majority of shareholders voting in person or by proxy, by the following approximate percentages of shares voting:

- Appointment of Prof. Yitzhak Peterburg as director 95%
- Appointment of Dr. Arie Belldegrun as director 94%
- Appointment of Mr. Amir Elstein as director 93%
- Amended Compensation Policy 81%
- With respect to the Terms of Office and Employment of the President and CEO, Mr. Erez Vigodman:
  - Approval of increases in his base salary 90%
  - Amendment to his annual cash bonus objectives and payout terms for 2016 and going forward 88%
  - Amendment to his annual equity awards for each year commencing in 2016 89%
- Amendment to the 2015 Equity-Based Incentive Plan to increase the number of shares available for issuance thereunder 90%
- Appointment of independent auditors 99%

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Date: April 18, 2016 By: /S/ EYAL DESHEH

Name: Eyal Desheh

Title: Group Executive Vice President, Chief Financial Officer